Biote Reports Second Quarter 2026 Financial Results
biote Corp. (BTMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Biote Reports Second Quarter 2026 Financial Results Continued progress in advancing strategic initiatives Updates full-year outlook Second Quarter 2026 Financial Highlights • Revenue of $44.2 million • Gross profit margin of 65.4% • Net loss of $(7.4) million and diluted loss per
How this was made
The 30-second read
Why it matters
Q2 showed revenue decline and a net loss, while management revised full-year expectations and guided to sequential procedure revenue improvement in Q3 and Q4, still with negative YoY procedure revenue due to first-half recall disruption.
Market read
This is a direct earnings and guidance update with explicit recall-related headwinds and a revised full-year revenue and Adjusted EBITDA outlook.
What to watch
The filing attributes margin weakness to higher-cost replacement sourcing and reduced manufacturing efficiencies at Asteria Health; traders may need to monitor whether those operational frictions normalize faster than the company’s implied timeline.
Background
Biote (BTMD) filed an 8-K with Q2 2026 financial results and an updated 2026 outlook, centered on impacts from a voluntary product recall initiated in January 2026.
Ticker impact
Biote reported Q2 2026 results and revised full-year outlook, citing voluntary hormone pellet recall impacts on procedure revenue and margins.
Likely downside or heightened volatility until investors gain confidence in sequential procedure revenue improvement in Q3 and Q4.
The filing discloses weaker Q2 profitability (net loss, lower Adjusted EBITDA) and explicitly revises procedure revenue expectations due to recall disruption, which typically pressures valuation multiples for small-cap healthcare names.
Market effects
Highlights execution and supply-chain risk in hormone pellet products, which can affect sentiment toward similar specialty healthcare procedure models.
No clear regional spillover beyond US small-cap healthcare sentiment.
Limited global relevance; story is company-specific and US-listed.
Counterpoint
If investors focus on the stated sequential improvement in procedure revenue in Q3 and Q4, the guidance reset could be viewed as de-risking rather than worsening.
Key entities
- companybiote Corp.
NASDAQ-listed hormone optimization and healthy aging solutions provider reporting Q2 2026 results and revised 2026 outlook.
- partner/supplierAsteria Health
Third-party pellet supplier whose manufacturing efficiencies were cited as reduced during recall replacement sourcing.
- executiveBob Peterson
Interim CEO who discussed strategic progress and recall impacts, and guided to sequential improvement in the second half.
